Precision BioSciences, Inc. (NASDAQ:DTIL) Given Average Rating of “Moderate Buy” by Brokerages

Precision BioSciences, Inc. (NASDAQ:DTIL) has been assigned an average rating of “Moderate Buy” from the five ratings firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $32.25.

Several equities research analysts have commented on DTIL shares. Oppenheimer began coverage on shares of Precision BioSciences in a research report on Tuesday, June 9th. They set an “outperform” rating and a $20.00 target price on the stock. Weiss Ratings upgraded Precision BioSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 8th. HC Wainwright restated a “buy” rating on shares of Precision BioSciences in a report on Monday. Finally, JonesTrading reiterated a “buy” rating and issued a $30.00 price target on shares of Precision BioSciences in a report on Friday, April 17th.

Institutional Trading of Precision BioSciences

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Aberdeen Group plc bought a new stake in Precision BioSciences during the fourth quarter valued at $8,897,000. Empery Asset Management LP acquired a new position in shares of Precision BioSciences during the fourth quarter valued at approximately $9,130,000. Affinity Asset Advisors LLC acquired a new stake in shares of Precision BioSciences during the 1st quarter valued at $3,289,000. Octagon Capital Advisors LP lifted its position in shares of Precision BioSciences by 16.6% in the 1st quarter. Octagon Capital Advisors LP now owns 2,236,732 shares of the company’s stock valued at $12,302,000 after acquiring an additional 318,737 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new stake in Precision BioSciences during the third quarter valued at $122,000. 37.99% of the stock is owned by hedge funds and other institutional investors.

Precision BioSciences Stock Up 3.1%

Precision BioSciences stock opened at $7.28 on Wednesday. The stock has a 50 day moving average of $7.34 and a two-hundred day moving average of $6.28. Precision BioSciences has a twelve month low of $3.53 and a twelve month high of $9.62. The company has a current ratio of 14.02, a quick ratio of 14.02 and a debt-to-equity ratio of 0.29. The stock has a market capitalization of $187.82 million, a price-to-earnings ratio of -1.98 and a beta of 1.27.

Precision BioSciences (NASDAQ:DTIL) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.09). The firm had revenue of $10.84 million during the quarter, compared to analyst estimates of $4.05 million. Precision BioSciences had a negative net margin of 96.73% and a negative return on equity of 85.37%. As a group, research analysts expect that Precision BioSciences will post -2.21 earnings per share for the current year.

Precision BioSciences Company Profile

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.